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Abstract
Background: The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of
bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV
metastatic cutaneous melanoma in a phase 2, proof-of-concept study.
Results: Eligible patients had metastatic cutaneous melanoma naïve to chemotherapy or immunotherapy, no
central nervous system involvement, and serum lactate dehydrogenase <1.5 × upper limit of normal. Treatment
comprised bosentan 500 mg twice daily or matching placebo, in addition to dacarbazine 1000 mg/m
2 every three
weeks. Eighty patients were randomized (double-blind) and 38 in each group received study treatment. Median
time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8
months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% CI, 0.717-1.827; p = 0.5683). Incidences of
most adverse events and clinically relevant increases in hepatic transaminases were similar between treatment
groups although hemoglobin decrease to >8 and ≤ 10 g/dL and ≤ 8 g/dL was more common in the bosentan
group.
Conclusions: In patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of
high-dose bosentan had no effect on time to tumor progression or other efficacy parameters. There were no
unexpected safety findings.
Trial registration: This study is registered in ClinicalTrials.gov under the unique identifier NCT01009177.
Background
Each year there are approximately 160,000 new cases of
malignant melanoma worldwide and it is responsible for
an estimated 41,000 deaths [1]. The incidence is cur-
rently increasing and predicted to continue increasing
for the next 20 years or more [2]; mortality is also
increasing in many countries, including Europe and
Australia [3]. The prognosis for patients with distant
metastases from melanoma is poor; patients with ele-
vated serum lactate dehydrogenase or extra-pulmonary
visceral involvement have a median survival of just 4-6
months and a 2-year survival rate of ≤ 5% [4]. No
systemic therapy has been shown in phase III trials to
be superior to single agent treatment with dacarbazine.
However, response rates of only 8-15% have been
reported for this approach in randomized controlled
trials [5-10]. Neither combination chemotherapy with
tamoxifen [6] nor an intensive three-drug regimen with
interferon-2-alpha and interleukin-2 showed any survival
advantage over dacarbazine alone [11]. The addition of
the anti-bcl2 oligonucleotide oblimersen showed no
overall survival benefit over dacarbazine alone, except in
a low lactate dehydrogenase (LDH) subgroup [9]. The
dacarbazine-sensitizing drug lomeguatrib also showed
no superiority in a double blind trial [12].
The endothelin (ET) pathway is involved in a number
of aspects of melanocyte physiology and in the
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(ETB) receptor is expressed in primary and metastatic
malignant melanoma, and increased expression of ETB
correlates with tumor progression in malignant mela-
noma [15]. In addition, activation of the ETB receptor,
by ET-1 and ET-3, results in downstream activation of
tumor-promoting events and the progression of cuta-
neous melanoma [16].
The oral dual ET-receptor antagonist bosentan (Tracl-
eer®, Actelion Pharmaceuticals Ltd.), indicated for the
treatment of pulmonary arterial hypertension (PAH),
blocks both ETA and ETB receptors. In human mela-
noma cell lines, bosentan has been observed to inhibit
proliferation [13,17], decrease cell viability and DNA
synthesis, and induce apoptosis [18]. Bosentan has also
been shown to potentiate the effects of alkylating agents
[18].
The results of a single-arm, phase II uncontrolled
study indicated that bosentan monotherapy may be of
benefit in patients with stage IV metastatic melanoma,
achieving disease stabilization in six of 32 patients
(18.8%) at week 6, with confirmation at week 12; five
patients were still stable after 24 weeks and two
remained stable after more than 2 years on study treat-
ment [17]. We therefore hypothesized that ET receptor
inhibition with bosentan may improve the efficacy of
dacarbazine as therapy for metastatic melanoma, when
the two agents are given in combination. The rando-
mized, placebo-controlled, add-on phase 2, proof-of-
concept, event-driven study presented here was con-
ducted primarily to evaluate the effect of bosentan and
placebo on time to tumor progression in patients with
stage IV metastatic melanoma starting treatment with
dacarbazine.
Methods
Patients
Patients eligible for the study were at least 18 years of
age with histologically-proven malignant melanoma [4]
and stage IV measurable disease as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) [19]. No
prior therapy with dacarbazine was permitted and any
prior radiation therapy was required to have been >30
days before study drug administration, with indicator
lesions being either outside of the field of radiation or
new, non-irradiated, lesions. Eastern-Cooperative Oncol-
ogy Group (ECOG) performance status was required to
be ≤ 2 and life expectancy >12 weeks. Female patients
were required not to be pregnant or breastfeeding, and
to be either post-menopausal, surgically sterile, or prac-
ticing a reliable method of contraception.
The main criteria for exclusion from the study were:
lactate dehydrogenase >1.5 times the upper limit of nor-
mal (ULN); alanine aminotransferase (ALT) and/or
aspartate aminotransferase (AST) >3 times the ULN at
screening or ALT and/or AST >2 times the ULN and
total bilirubin >2.0 mg/dL at screening; hemoglobin
>30% below the lower limit of normal; central nervous
system metastases or leptomeningeal metastases; any
prior chemotherapy, biological therapy or immunother-
apy for stage IV metastatic disease; immunotherapy <30
days before treatment start; ocular melanoma; known
hypersensitivity to any excipients of bosentan; history of
other malignancy in the past 5 years, with the exception
of squamous cell carcinoma of the skin treated with
local resection and basal cell carcinoma; planned use (or
use within 4 weeks of the start of bosentan dosing) of
another investigational drug; any standard contraindica-
tions to dacarbazine. Concurrent use of calcineurin inhi-
bition, sirolimus, fluconazole or glyburide was not
permitted. The study was conducted in full compliance
with the principles of the Declaration of Helsinki and
Good Clinical Practice. Local institutional review boards
or independent ethics committees approved the protocol
and all patients gave written informed consent.
Treatment
Treatment with dacarbazine 1000 mg/m
2 every 3 weeks
starting on Day 1 of the study was mandatory for all
patients. In addition, eligiblep a t i e n t sw e r er a n d o m i z e d
in a 1:1 double-blind manner to receive bosentan or
matching placebo. Bosentan was administered orally
with or without food at a dose of 500 mg twice a day
(1000 mg total daily dose). This dose, equivalent to four
times the standard daily bosentan dose used in the
treatment of PAH, was selected on the basis of an ear-
lier phase II study [17] and in vitro data from melanoma
cell lines [13] in order to achieve maximum potential
exposure. Four tablets (125 mg per tablet) were taken in
the morning and four tablets approximately 12 hours
later. Down-titration to 250 mg twice a day or 125 mg
twice a day was allowed if the target study medication
dose was not tolerated; however, it was recommended
to maintain the full dose wherever possible.
Evaluations
Tumor measurements including chest X-ray, computer-
ized tomography scan, or magnetic resonance imaging
were performed on Day 1, Week 6, every 6 weeks dur-
ing dosing, and one week after the end of treatment.
Assessment for tumor progression/response was per-
formed at Week 6, every 6 weeks during dosing and one
week after the end of treatment according to RECIST
[19]. Patients underwent a series of laboratory tests
including assessment of hematology (hemoglobin, hema-
tocrit, erythrocyte count, leukocytes, platelets), liver
function (ALT, AST, alkaline phosphatase, total and
direct bilirubin) and chemistry (lactate dehydrogenase,
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ables; these were performed at screening, Weeks 1-6, 8,
9, 12 and every 3 weeks thereafter during dosing, and at
1 and 4 weeks after the end of treatment. Assessments
were scheduled for adverse events and serious adverse
events on Day 1, at Weeks 1-6, 8, 9, 12 and every 3
weeks thereafter during dosing, and one week after the
end of treatment. All new adverse events up to 24 hours
after study drug discontinuation, and all new serious
adverse events and grade 4/5 adverse events (National
Cancer Institute Common Terminology Criteria for
Adverse Events [NCI-CTCAE]) were reported up to 28
days after the end of treatment.
Endpoints
The primary efficacy endpoint was time to tumor pro-
gression. Time to tumor progression was measured
from randomization to the start of the first occurrence
of one the following: objective or subjective (as per
investigator’s judgment) tumor progression; death due
to disease progression; and initiation of other or addi-
tional anti-tumor therapy in the absence of documented
tumor progression.
In the absence of an event as described above, patients
were right censored at the last date of tumor assessment
or at the randomization date in absence of post-rando-
mization measurements. This rule was followed for
patients on study treatment; patients being followed on
study but off study treatment; patients lost to follow-up;
patients withdrawn from the trial in the absence of pro-
gressive disease; and patients who died due to non-can-
cer-related causes. Secondary endpoints included
progression-free survival and overall survival.
Safety endpoints included the incidence of treatment-
emergent adverse events (NCI-CTCAE) occurring dur-
ing and up to 1 day after end of study treatment; inci-
dence of serious adverse events up to 28 days after end
of study treatment; adverse events that led to disconti-
nuation or dose reduction; incidences of worst CTCAE
grade laboratory abnormalities during and up to 28 days
after the end of study treatment; incidences of hemoglo-
bin >8 and ≤ 10 g/dL, and ≤ 8 g/dL, with decrease from
baseline; liver aminotransferases ≥ 3t i m e st h eU L N ;
total bilirubin ≥ 2 times the ULN with ALT and/or
AST ≥ 3 times the ULN; increased blood alkaline
phosphatase.
Statistical methods
A total of 66 events were required at outset to detect a
bosentan vs placebo hazard ratio (HR) of 0.5 with a
type-I error of 0.05 (two-sided) and 80% power using
the log-rank test to compare the distribution of time to
tumor progression for the two treatment groups.
Assuming enrolment of 70 patients (1:1 randomization)
over 70 weeks, 66 events were expected to occur within
105 weeks if the median time to tumor progression was
10 weeks in the placebo group and the HR was 0.5. Effi-
cacy data were analyzed on the all-randomized popula-
tion comprising all randomized patients, whether or not
they received any study drug. Safety data were analyzed
on the all-treated population comprising all randomized
patients who received study drug.
Results
Baseline demographics
The study was performed in 11 centers in Australia,
with the first patient, first visit in September 2005 and
the last patient, last visit in February 2008. A total of 80
patients were randomized; however, two patients in each
group did not receive any study treatment due to with-
drawal of consent or randomization error by the phar-
macy (Figure 1), and were excluded from the safety
evaluation.
Baseline demographics are summarized in Table 1.
Compared with the placebo group, the bosentan group
comprised a higher proportion of males and the mean
age of patients was slightly higher. The median number
of target and non-target lesions was five (min, 2; max,
9) in the placebo group and five (min, 1; max, 10) in the
bosentan group, the most common sites being the lung
(placebo, 81.6%; bosentan, 59.0%), lymph nodes (31.6%;
38.5%), adrenal glands (5.3%; 28.2%), soft tissue (21.1%;
25.6%) and liver (18.4%; 23.1%). The percent of patients
with lactate dehydrogenase levels ≤ ULN and >ULN was
similar between the two treatment groups, and mean
and median levels were comparable.
Exposure
In each group, 38 patients were treated and evaluable
for exposure. For dacarbazine, the mean (± standard
deviation) number of cycles administered was 5.5 (± 4.5)
in the placebo plus dacarbazine treatment group and 4.8
(± 4.1) in the bosentan plus dacarbazine treatment
group. Median duration of dacarbazine exposure (min;
max) was 12.0 weeks (3.0; 61.0) and 7.5 weeks (3.0;
51.1) in the two treatment groups, respectively. The
median daily exposure for bosentan (min; max) was
1000 mg (125 mg; 1000 mg) and the median duration of
exposure (min; max) was 8.1 weeks (3.0; 71.0).
Efficacy
The primary endpoint, time to tumor progression, was
not significantly different between the treatment groups,
with a median of 2.8 months (95% CI, 1.4-4.1) for pla-
cebo and 1.6 months (95% CI, 1.3-4.0) for bosentan
(HR, 1.144; 95% CI, 0.717-1.827; p = 0.5683) (Figure 2a).
Supportive analysis on the all treated and per-protocol
sets showed similar results (data not shown).
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ure 2b) and progression-free survival were also not signifi-
cantly different between treatment groups. Median overall
survival was 10.6 months (95% CI, 6.9-14.7) with placebo
and 13.0 months (7.8-16.6) with bosentan (HR, 1.044; 95%
CI, 0.584-1.865; p = 0.8841) (Figure 2b). The Kaplan-
Meier estimate for overall survival at 12 months was
42.1% (95% CI, 25.8-58.4) and 52.1% (95% CI, 35.1-69.1)
for the two treatment groups, respectively. Median pro-
gression-free survival was 2.8 months (95% CI, 1.4-4.1) for
placebo and 1.6 months (95% CI, 1.3-4.1) for bosentan
(HR, 1.064; 95% CI, 0.664-1.704; p = 0.7944). The Kaplan-
Meier estimate for progression-free survival at 6 months
was 18.9% (95% CI, 6.3-31.6) and 27.0% (95% CI, 12.7-
41.3) for the two treatment groups, respectively.
Safety and tolerability
Adverse events occurring during and up to 1 day after
the end of study treatment are shown in Table 2. All
but one patient experienced an adverse event and
similar proportions of patients in the two groups experi-
enced a serious adverse event (placebo plus dacarbazine,
31.6%; bosentan plus dacarbazine, 34.2%). Anemia,
thrombocytopenia, vomiting and lethargy were more
common among patients receiving bosentan than pla-
cebo (all NCI CTCAE grades; ≥ 10% total difference).
Conversely, fatigue, headache, dyspnea and upper
respiratory tract infection were more common among
patients receiving placebo.
Hematology assessment was graded according to the
NCI CTCAE system and is reported in Table 3 as inci-
dences of worst grades experienced during and up to 28
days after the end of study treatment. Grade 4 events
occurred in two patients: one patient (2.6%) in the pla-
cebo plus dacarbazine group had Grade 4 reduction in
neutrophils and one patient (2.6%) in the bosentan plus
dacarbazine group had Grade 4 reduction in hemoglo-
bin. Grade 3 hematology abnormalities occurred in no
more than two patients (5.3%) in either treatment arm
for any variable. Grades 2, 3, and 4 reductions in
Figure 1 Patient flow through the study. Patient flow through the study:
1Including adverse events relating to disease progression;
2Unrelated
to disease progression;
3Includes one patient in each group who discontinued due to study closure;
4Efficacy was analyzed on the all-
randomized set; however, one patient, randomized to placebo, did not receive any study treatment, had no post-baseline tumor assessments,
and had data missing for the date of randomization at the time of database closure. Because time-to-event analyses required a randomization
date, this patient could not be included in these analyses, including the primary endpoint.
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bosentan plus dacarbazine treatment group than in the
placebo plus dacarbazine treatment group.
Clinically significant laboratory abnormalities were
also documented. Four patients (10.5%) in each treat-
ment group had liver aminotransferases ≥ 3t i m e st h e
ULN; 3 (7.9%) in each group had liver aminotransferases
≥ 3 and <5 times the ULN; and 1 (2.6%) in each group
had liver aminotransferases ≥ 5 and <8 times the ULN.
No patient in either treatment group experienced ami-
notransferase elevations ≥ 8 times the ULN. Reductions
in hemoglobin, with decreases from baseline, occurred
more often in the group receiving bosentan plus dacar-
bazine than the group receiving placebo plus dacarba-
zine: hemoglobin decreased to >8 and ≤ 10 g/dL in 10
patients (26.3%) and to ≤ 8 g/dL in 3 patients (7.9%)
with bosentan plus dacarbazine; the corresponding
c h a n g e so c c u r r e di no n l yo n ep a t i e n t( 2 . 6 % )e a c hw i t h
placebo plus dacarbazine. No patients experienced bilir-
ubin ≥ 2 times the ULN.
There were three deaths among patients receiving
bosentan (all attributed to disease progression, with
additional ascites in one case and hyponatremia in
another case) and two deaths among patients receiving
placebo (one due to disease progression and one due to
cerebrovascular accident). All of the five deaths occurred
after study treatment was stopped (during the 28-day
follow-up) and none were considered, by the investiga-
tors, to be related to study treatment.
Adverse events were responsible for premature treat-
ment discontinuation in two patients in the placebo plus
dacarbazine group and three patients in the bosentan
plus dacarbazine treatment group. In the placebo plus
dacarbazine group, one of the two patients had an
adverse event denoting disease progression and the
other had an increase in serum ALT and alkaline phos-
phatase levels that was considered to be related to treat-
ment and led to discontinuation of both placebo and
dacarbazine. In the bosentan plus dacarbazine group,
two of the three patients had adverse events denoting
disease progression and the other had anorexia, fatigue
and nausea, with the fatigue and nausea considered to
be related to both bosentan and dacarbazine.
Discussion
In this multicenter, randomized, double-blind, placebo-
controlled, phase 2, proof-of-concept study, the addition
of high-dose bosentan to treatment in patients receiving
first-line dacarbazine for stage IV metastatic melanoma
had no effect on time to tumor progression, overall sur-
vival or progression-free survival. For the primary end-
point of time to tumor progression, the median
duration was 2.8 months among patients who received
placebo and dacarbazine and 1.6 months among those
who received bosentan and dacarbazine.
Previous studies with dacarbazine in metastatic mela-
noma have demonstrated median time to tumor pro-
gression of 2.3 to 2.7 months [5,8], progression-free
survival of 1.5 to 2.7 months [5,7,9] and overall survival
of 6.3 to 10.4 months [5-9]. The median overall survival
observed in the placebo arm of the present study (10.6
months) is at the top of the previously reported range
for dacarbazine monotherapy. The median overall survi-
val in the bosentan arm (13.0 months) is also relatively
high for a combination treatment in this setting [5-9]. A
meta-analysis of 42 phase II trials in metastatic mela-
noma suggested that an agent in phase II testing should
reach a 6-month progression-free survival of approxi-
mately 25% and a 12-month overall survival of approxi-
mately 45% to be considered for further evaluation in
phase III [20]. In this study, PFS at 6 months was 18.9%
with placebo and 27.0% with bosentan and overall
Table 1 Baseline demographics and clinical
characteristics
Parameter Placebo +
dacarbazine
(n = 40)*
Bosentan +
dacarbazine
(n = 40)*
Sex
Male, n (%) 22 (55.0) 28 (70.0)
Female, n (%) 18 (45.0) 12 (30.0)
Mean age ± SD, years 58.0 ± 14.8** 62.1 ± 12.2
ECOG performance status, n (%)
0 29 (72.5) 27 (67.5)
1 7 (17.5) 11 (27.5)
2 4 (10.0) 2 (5.0)
Lactate dehydrogenase Placebo +
dacarbazine
(n = 38)
†
Bosentan +
dacarbazine
(n = 38)
†
≤ ULN, n (%) 25 (67.5)
‡ 26 (38.4)
> ULN, n (%) 12 (37.4)
‡ 12 (31.5)
Mean ± SD, U/L 351 ± 199
‡ 337 ± 178
Median [min, max], U/L 279 [99, 813]
‡ 259 [129, 774]
Previous medications for stage I-III
melanoma
Placebo +
dacarbazine
(n = 38)
†
Bosentan +
dacarbazine
(n = 38) †
Any previous treatment, n (%) 9 (23.7) 9 (23.7)
Immunostimulants 4 (10.5) 7 (18.4)
Interferons 4 (10.5) 1 (2.6)
Anti-neoplastic agents 1 (2.6) 1 (2.6)
Other investigational drug 1 (2.6) 1 (2.6)
SD, standard deviation of the mean; ECOG, Eastern Cooperative Oncology
Group; ULN, upper limit of normal (value set by each local site, as per their
normal practice)
* All-randomized set
** n = 39 (one patient missing randomization date; calculation of age not
possible)
† All-treated population; data not available for 2 patients in each group (due
to consent withdrawal or randomization error)
‡ n = 37 (one patient missing)
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with bosentan. These figures lie in the upper quartile of
values found in that meta-analysis and this may be
partly attributed to the stringent selection criteria of no
central nervous system metastases and low serum LDH.
This proof-of-concept study was designed to demon-
s t r a t ea5 0 %r i s kr e d u c t i o ni nf a v o ro fb o s e n t a ni nt i m e
to tumor progression. Though this may seem ambitious,
a hazard ratio of 0.5 in an event-driven trial of a drug
given at high dose is not unrealistic in a phase 2, proof-
of-concept study.
Bosentan has been extensively studied in patients with
PAH in both randomized clinical trials and post-market-
ing surveillance [21-24]. This study in patients with
melanoma used a dose of bosentan four times higher
than the standard dose in PAH. Nevertheless, treatment
was generally well tolerated in both the bosentan and
placebo groups, and only five patients in total discontin-
ued from the study due to adverse events. There were
no deaths during the study treatment period and none
considered to be related to treatment. Similarly, there
were no unexpected safety concerns in the previous
phase II study of bosentan monotherapy in metastatic
melanoma [17], which used the same bosentan dose
(500 mg twice daily) as the present study. Elevation of
hepatic aminotransferases is an ET receptor antagonist
class effect and is associated with their chronic use in
PAH [24-26]. The incidence of clinically relevant
Figure 2 Primary and secondary efficacy endpoints: Kaplan-Meier estimates of time to progression and overall survival.K a p l a n - M e i e r
estimates of A) time to progression and B) overall survival (all-randomized population).
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in our study in patients with melanoma is within the
range reported for PAH patients receiving bosentan 125
mg bid [23,24,27].
In the present study, bosentan and placebo were admi-
nistered in combination with first-line dacarbazine. The
safety profile of dacarbazine is well established in the treat-
ment of metastatic melanoma. Adverse events known to
be associated with dacarbazine include myelosuppression
(thrombocytopenia, anemia, and neutropenia), nausea and
vomiting [reviewed in [28]]. Adverse events reported in
the placebo arm of the present study were broadly in line
with those reported for dacarbazine, although only one
case (2.6%) of NCI-CTCAE anemia was reported in the
placebo plus dacarbazine group, which is lower than
might be expected based on historical data.
A decision was made when planning the study not to
restrict accrual to patients with readily accessible tumor
for fresh biopsy; subsequently, few tumor biopsy sam-
ples were obtained. This restricted ET receptor analysis
as it can only be assayed in fresh frozen material by
reverse-transcriptase polymerase chain reaction and is
not amenable to immunohistochemical evaluation.
Hence, it is not possible to comment on whether ET
receptor expression was related to response to treat-
ment. In the previous phase II study, a limited number
of assays were performed; no correlation between ET
receptor expression and response was observed [17].
Conclusion
The addition of high-dose bosentan had no effect on
time to tumor progression or other efficacy parameters
Table 2 Incidence of NCI-CTCAEs up to one day post study treatment (all-treated population)
Placebo + dacarbazine
(n = 38)
Bosentan + dacarbazine
(n = 38)
Event Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Patients with at least one AE, n (%) 37 (97.4) 9 (23.7) 1 (2.6) 38 (100)** 14 (36.8) 1 (2.6)
Patients with AE,* n (%)
Nausea 19 (50.0) - - 22 (57.9) 1 (2.6) -
Fatigue 19 (50.0) - - 14 (36.8) 2 (5.3) -
Constipation 10 (26.3) - - 12 (31.6) - -
Vomiting 8 (21.1) - - 12 (31.6) 2 (5.3) -
Thrombocytopenia 4 (10.5) 1 (2.6) - 9 (23.7) 2 (5.3) 1 (2.6)
Headache 11 (28.9) 1 (2.6) - 7 (18.4) - -
Anemia 1 (2.6) - - 7 (18.4) 2 (5.3) 1 (2.6)
Anorexia 7 (18.4) - - 6 (15.8) - -
Diarrhea 7 (18.4) - - 6 (15.8) - -
Neutropenia 5 (13.2) 2 (5.3) 1 (2.6) 6 (15.8) 5 (13.2) -
Lethargy 2 (5.3) - - 6 (15.8) - -
Dyspnea 9 (23.7) 3 (7.9) - 5 (13.2) 2 (5.3) -
Cough 6 (15.8) - - 5 (13.2) - -
Pain in extremity 4 (10.5) 1 (2.6) - 5 (13.2) 1 (2.6) -
Edema peripheral 3 (7.9) - - 5 (13.2)† --
Insomnia 5 (13.2) - - 4 (10.5) - -
Alanine aminotransferase
increased
3 (7.9) - - 4 (10.5) 1 (2.6) -
AE, adverse event
* ≥ 10% frequency in bosentan + dacarbazine group; **one patient had a Grade 5 event (metastatic malignant melanoma/malignant neoplasm progression);
†data missing for one patient
Table 3 Incidence of worst NCI-CTCAE hematology grades during and up to 28 days after the end of study treatment
(all-treated population)
Placebo + dacarbazine
(n = 38)
Bosentan + dacarbazine
(n = 38)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin, n (%) 26 (68.4) 2 (5.3) - - 19 (50.0) 9 (23.7) 1 (2.6) 1 (2.6)
Leukocytes, n (%) 8 (21.1) 6 (15.8) 2 (5.3) - 10 (26.3) 7 (18.4) 1 (2.6) -
Neutrophils, n (%) 4 (10.5) 5 (13.2) 2 (5.3) 1 (2.6) 3 (7.9) 8 (21.1) 1 (2.6) -
Platelets, n (%) 11 (28.9) 3 (7.9) - - 10 (26.3) 3 (7.9) 2 (5.3) -
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therapy for metastatic melanoma. The results of our
study further highlight the challenges of treating meta-
static melanoma and, in particular, improving outcomes
beyond the modest benefits achieved with dacarbazine
monotherapy.
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